The spectrum of clinical and histopathological features in patients undergoing liver biopsy for immune-checkpoint-inhibitor-associated hepatotoxicity: a 10-year multicentre experience

Key Points

• Hepatotoxicity manifests in a diverse array of clinical and histopathological features, necessitating comprehensive evaluation.
• The analysis reveals significant variances in liver biopsy findings related to immune-checkpoint inhibitor therapy across different centers.
• Observations detail liver biopsy results from patients who experienced hepatotoxicity after immune-checkpoint inhibitor treatments over a decade.
• The findings underscore the importance of monitoring for diverse liver-related issues in patients undergoing such therapies.